A Waikato police officer has been told to consider a move to Australia to treat his cancer. Will Hamilton was diagnosed with blood cancer multiple myeloma in November 2022, a day after he and his partner Amber found out they were pregnant with their second child. Read the full article here: Father of two told...Continue Reading
The Shawview Report, commissioned by Johnson & Johnson, is a valuable, timely round-up of the inherent problems in our medicines funding system and offers some good solutions, including innovative funding mechanisms in action in other countries, as well as the immediate need to fund Pharmac’s current backlog of approved medicines waiting for funding. If...Continue Reading
The silken ropes holding 26 pearls around Jacq Dwyer’s neck are a beautiful reminder of her victory over a devastating illness, but one she will fight for the rest of her life. Dwyer is well known in South Taranaki as an advocate for her Pātea community, a historian, author, a cancer survivor and baker of...Continue Reading
In the first two months of 2021, 27 patients were harmed by cancer treatment delays, the Otago Daily Times reported. Three became so sick while waiting they were unfit for treatment. Have you been affected? Please email: newsdesk@nzherald.co.nz Please read more here: Cancer patients harmed by treatment delaysContinue Reading
Myeloma New Zealand has made a submission on the Therapeutic Products Bill, as it has implications for Myeloma Patients. The Chair of the Health Committee has called for public submissions on the Therapeutic Products Bill. Therapeutic Products are medicines, medical devices, natural health products, and pharmaceutical ingredients. The bill seeks to provide for the regulation...Continue Reading
The Australasian Myeloma Research Consortium (AMaRC) in collaboration with theAustralasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related DiseasesRegistry (MRDR) is conducting a phase II study to investigate the optimal usage oflenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma patientsbased on a frailty score (frailty is characterised by a decline in body functions). If...Continue Reading
The New Zealand Myeloma Interest Group is comprised of representative haematologists from District Health Boards around the country with a special interest and expertise in MM. We reviewed the currently available evidence, including randomised controlled trials, retrospective data and conference abstracts, and interpreted these in the context of treatment options available in New Zealand to...Continue Reading
Myeloma experts convened in person and online for the 2022 Multiple Myeloma Queenstown Summit, hosted by Myeloma New Zealand. This year’s meeting included presentations from local and international experts, including the Chief Medical Officer of the International Myeloma Foundation, Professor Joseph Mikhael, Assistant Professor Jonathan Keats from Arizona, and Professor Simon Harrison and Dr Simon...Continue Reading
Myeloma New Zealand has started a campaign to press Pharmac into funding a treatment that has been standard-of-care throughout the Organisation for Economic Co-operation and Development (OECD) for more than five years. Myeloma NZ trustee Nichola Oakenfull has been interviewed for the article, well done Nichola! Here is the RNZ article: https://www.rnz.co.nz/news/national/474629/blood-cancer-patient-charity-campaigns-for-pharmac-to-fund-medicineContinue Reading
